Iceland· IS-EU/1/14/943/001-004
Velphoro
A sucroferric oxyhydroxide product containing sucroferric oxyhydroxide, registered in Iceland by Vifor Fresenius Medical Care Renal Pharma France*. The same ATC class is registered in 12 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Sucroferric oxyhydroxide is registered in 12 of 19 countries.
Countries holding a registration under ATC V03AE05 (sucroferric oxyhydroxide), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 7 of them publish a price we can compare per daily dose
Sucroferric oxyhydroxide · ATC V03AE05
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of sucroferric oxyhydroxide costs, country by country.
Normalised to the WHO defined daily dose (1.5 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Sucroferric oxyhydroxide · price per daily dose (1.5 g)
USD · FX 28 Sept 2026
- CH Switzerland$1.80
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Sucroferric oxyhydroxide
- Manufacturer
- Vifor Fresenius Medical Care Renal Pharma France*
- Country
- Iceland (IS)
- ATC code
- V03AE05
- ATC class
- Sucroferric oxyhydroxide
- Defined daily dose
- 1.5 g, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sucroferric oxyhydroxide in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainVelphoro 500 mg comprimidos masticablesVifor Fresenius Medical Care Renal Pharma France
- FranceVELPHORO 500 mg, comprimé à croquerVIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE
- BelgiumVelphoro 500 mgVifor Fresenius Medical Care Renal Pharma France
- NorwayVelphoroVifor Fresenius Medical Care Renal Pharma France (1)
- SwedenVelphoro 500 mg TuggtablettVifor Fresenius Medical Care Renal Pharma France
- United StatesVelphoroFresenius Medical Care Renal Therapies Group, LLC
- United KingdomVelphoro 500mg chewable tabletsVifor Fresenius Medical Care Renal Pharma UK Ltd
- Japanスクロオキシ水酸化鉄キッセイ薬品工業
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Velphoro
- Norway · Velphoro
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b197f69d-b9ba-4af9-a09e-396e9b07a2e5 GET /v1/drugs/b197f69d-b9ba-4af9-a09e-396e9b07a2e5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tuggutafla",
"source": "lyfjastofnun",
"atc_raw": "V03AE05",
"marketed": false,
"strength": "500 mg",
"ma_number": "EU/1/14/943/001-004",
"substance": "Sucroferric oxyhydroxide",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í nýrnasjúkdómum.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "41877"
}See everything about sucroferric oxyhydroxide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.